Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.

Oncology research and treatment - 1 Jan 2020

Kauffmann-Guerrero Diego, Tufman Amanda, Kahnert Kathrin, Bollmann Benjamin Alexander, Reu Simone, Syunyaeva Zulfiya, Schneider Christian, Manapov Farkhad, Huber Rudolf M, Golpon Heiko

Abstract excerpt

AIMS: Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in NSCLC with other driver mutations. The increasing use of next-generation sequencing (NGS) leads to molecular findings that face the clinician with problems while choosing the best treatment. This study aims at analyzing response of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Class I Phosphatidylinositol 3-Kinases

Share to ErbB Receptors

Share to Nivolumab

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 32268332
DOI: 10.1159/000506842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.PMID 32268332Read ↗

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.Semantic proximity Read ↗

Immunotherapy in non-small cell lung cancer harbouring driver mutations.Semantic proximity Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.Semantic proximity Read ↗

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.Semantic proximity Read ↗

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations.Semantic proximity Read ↗

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.